Veraxa Biotech AG (VRXA) Income Statement
VRXA 2025 at a glance
Fiscal year ended December 31, 2025 · Swiss francsVRXA revenue and net income
Where VRXA's revenue goes
2025Each bar shows an amount and its share of revenue. VRXA kept −284,359.2% of revenue as net income.
VRXA profit margins
VRXA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
VRXA income statement in Swiss francs
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | CHF 23,426 | CHF 0 | CHF 0 |
| Cost of revenue | CHF 7,965 | CHF 0 | — |
| Gross profit | CHF 15,461 | CHF 0 | — |
| Research & development | CHF 10.3M | CHF 6.3M | CHF 4.3M |
| Sales, general & admin | CHF 53.9M | CHF 20.7M | CHF 10.5M |
| Total operating expenses | CHF 66.2M | CHF 28.9M | CHF 16.7M |
| Operating income | −CHF 66.2M | −CHF 28.9M | −CHF 16.7M |
| Interest expense | CHF 3,552 | CHF 291 | CHF 1,090 |
| Income before taxes | −CHF 67.0M | −CHF 28.8M | −CHF 17.7M |
| Net income | −CHF 66.6M | −CHF 28.1M | −CHF 16.5M |
| EBITDA | −CHF 64.9M | −CHF 26.9M | −CHF 15.8M |
| Gross margin | 66.0% | — | — |
| Operating margin | −282,662.7% | — | — |
| Net margin | −284,359.2% | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in Swiss francs as reported in VRXA's financial statements (latest annual report filed —); data from EODHD. Sales, general & administrative expenses include sales and marketing.
VRXA financial results
In fiscal year 2025 (ended December 31, 2025), Veraxa Biotech reported revenue of CHF 0.0 million. It had a net loss of CHF 66.6 million, a net profit margin of −284,359.2%. Figures are in Swiss francs, the currency of its financial statements.
See the VRXA stock overview for the latest quote and news, or the VRXA chart for price history and technical indicators.
VRXA income statement FAQ
What is Veraxa Biotech's annual revenue?
Veraxa Biotech reported total revenue of CHF 0.0 million for fiscal year 2025, which ended on December 31, 2025.
Is Veraxa Biotech profitable?
No. Veraxa Biotech reported a net loss of CHF 66.6 million in fiscal 2025, a net profit margin of −284,359.2%; its operating margin was −282,662.7%.
What is Veraxa Biotech's gross margin?
Veraxa Biotech's gross margin was 66.0% in fiscal 2025: for every $100 of revenue, Veraxa Biotech kept $66 after the direct cost of its products and services.
How much does Veraxa Biotech spend on research and development?
Veraxa Biotech spent CHF 10.3 million on research and development in fiscal 2025, 43,815.1% of revenue.
When does Veraxa Biotech's fiscal year end?
Veraxa Biotech's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025.